TY - JOUR
T1 - Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model
AU - Julien, S.
AU - Picco, G.
AU - Sewell, R.
AU - Vercoutter-Edouart, A-S
AU - Tarp, M.
AU - Miles, D.
AU - Clausen, H.
AU - Taylor-Papadimitriou, J.
AU - Burchell, J. M.
PY - 2009/6/2
Y1 - 2009/6/2
N2 - Changes in the composition of glycans added to glycoproteins and glycolipids are characteristic of the change to malignancy. Sialyl-Tn (STn) is expressed by 25-30% of breast carcinomas but its expression on normal tissue is highly restricted. Sialyl-Tn is an O-linked disaccharide that can be carried on various glycoproteins. One such glycoprotein MUC1 is expressed by the vast majority of breast carcinomas. Both STn and MUC1 have been considered as targets for immunotherapy of breast cancer patients. Here we used different immunogens to target STn in an MUC1 transgenic mouse model of tumour challenge. We show that synthetic STn coupled to keyhole limpet haemocyanin (Theratope), induced antibodies to STn that recognised the glycan carried on a number of glycoproteins and in these mice a significant delay in tumour growth was observed. The protection was dependant on STn being expressed by the tumour and was antibody mediated. Affinity chromatography of the STn-expressing tumour cell line, followed by mass spectrometry, identified osteopontin as a novel STn-carrying glycoprotein which was highly expressed by the tumours. These results suggest that if antibodies can be induced to a number of targets expressed by the tumour cells, a humoral response can be effective in controlling tumour growth. British Journal of Cancer (2009) 100, 1746-1754. doi: 10.1038/sj.bjc.6605083 www.bjcancer.com Published online 12 May 2009 (C) 2009 Cancer Research UK
AB - Changes in the composition of glycans added to glycoproteins and glycolipids are characteristic of the change to malignancy. Sialyl-Tn (STn) is expressed by 25-30% of breast carcinomas but its expression on normal tissue is highly restricted. Sialyl-Tn is an O-linked disaccharide that can be carried on various glycoproteins. One such glycoprotein MUC1 is expressed by the vast majority of breast carcinomas. Both STn and MUC1 have been considered as targets for immunotherapy of breast cancer patients. Here we used different immunogens to target STn in an MUC1 transgenic mouse model of tumour challenge. We show that synthetic STn coupled to keyhole limpet haemocyanin (Theratope), induced antibodies to STn that recognised the glycan carried on a number of glycoproteins and in these mice a significant delay in tumour growth was observed. The protection was dependant on STn being expressed by the tumour and was antibody mediated. Affinity chromatography of the STn-expressing tumour cell line, followed by mass spectrometry, identified osteopontin as a novel STn-carrying glycoprotein which was highly expressed by the tumours. These results suggest that if antibodies can be induced to a number of targets expressed by the tumour cells, a humoral response can be effective in controlling tumour growth. British Journal of Cancer (2009) 100, 1746-1754. doi: 10.1038/sj.bjc.6605083 www.bjcancer.com Published online 12 May 2009 (C) 2009 Cancer Research UK
U2 - 10.1038/sj.bjc.6605083
DO - 10.1038/sj.bjc.6605083
M3 - Article
SN - 1532-1827
VL - 100
SP - 1746
EP - 1754
JO - BJC: British Journal of Cancer
JF - BJC: British Journal of Cancer
IS - 11
ER -
